Randomized Controlled Trial

. 2016 Sep 6;134(10):723-33.

doi: 10.1161/CIRCULATIONAHA.115.020829. Epub 2016 Aug 1.

Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition)

Affiliations

¹ From University of North Carolina, Chapel Hill (M.A.C.); Brigham and Women's Hospital, Heart and Vascular Center, Harvard Medical School, Boston, MA (D.L.B.); Columbia University, New York, NY (G.W.S.); University of Auckland, Auckland City Hospital, Auckland, New Zealand (H.D.W.); Université Paris-Diderot, Sorbonne Paris Cité, INSERM U-1148, DHU FIRE, Hópital Bichat, Assistance Publique-Hópitaux de Paris, Paris, France (P.G.S.); Institute of Cardiovascular Medicine and Science, National Lung and Heart Institute, Imperial College, Royal Brompton Hospital, London, United Kingdom (P.G.S.); Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA (C.M.G.); Kerckhoff Clinic and Thoraxcenter, Bad Nauheim, Germany (C.W.H.); Scripps Clinic, La Jolla, CA (M.J.P.); UOC Fondazione IRCCS Policlinico San Matteo, Pavia, Italy (S.L.); The Medicines Company, Parsippany, NJ (J.P., E.N.D.); and Stanford University, Palo Alto, CA (K.W.M., R.A.H.).
² From University of North Carolina, Chapel Hill (M.A.C.); Brigham and Women's Hospital, Heart and Vascular Center, Harvard Medical School, Boston, MA (D.L.B.); Columbia University, New York, NY (G.W.S.); University of Auckland, Auckland City Hospital, Auckland, New Zealand (H.D.W.); Université Paris-Diderot, Sorbonne Paris Cité, INSERM U-1148, DHU FIRE, Hópital Bichat, Assistance Publique-Hópitaux de Paris, Paris, France (P.G.S.); Institute of Cardiovascular Medicine and Science, National Lung and Heart Institute, Imperial College, Royal Brompton Hospital, London, United Kingdom (P.G.S.); Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA (C.M.G.); Kerckhoff Clinic and Thoraxcenter, Bad Nauheim, Germany (C.W.H.); Scripps Clinic, La Jolla, CA (M.J.P.); UOC Fondazione IRCCS Policlinico San Matteo, Pavia, Italy (S.L.); The Medicines Company, Parsippany, NJ (J.P., E.N.D.); and Stanford University, Palo Alto, CA (K.W.M., R.A.H.). dlbhattmd@post.harvard.edu.

PMID: 27482008
PMCID: PMC5006794
DOI: 10.1161/CIRCULATIONAHA.115.020829

Randomized Controlled Trial

Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition)

Matthew A Cavender et al. Circulation. 2016.

. 2016 Sep 6;134(10):723-33.

doi: 10.1161/CIRCULATIONAHA.115.020829. Epub 2016 Aug 1.

Affiliations

¹ From University of North Carolina, Chapel Hill (M.A.C.); Brigham and Women's Hospital, Heart and Vascular Center, Harvard Medical School, Boston, MA (D.L.B.); Columbia University, New York, NY (G.W.S.); University of Auckland, Auckland City Hospital, Auckland, New Zealand (H.D.W.); Université Paris-Diderot, Sorbonne Paris Cité, INSERM U-1148, DHU FIRE, Hópital Bichat, Assistance Publique-Hópitaux de Paris, Paris, France (P.G.S.); Institute of Cardiovascular Medicine and Science, National Lung and Heart Institute, Imperial College, Royal Brompton Hospital, London, United Kingdom (P.G.S.); Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA (C.M.G.); Kerckhoff Clinic and Thoraxcenter, Bad Nauheim, Germany (C.W.H.); Scripps Clinic, La Jolla, CA (M.J.P.); UOC Fondazione IRCCS Policlinico San Matteo, Pavia, Italy (S.L.); The Medicines Company, Parsippany, NJ (J.P., E.N.D.); and Stanford University, Palo Alto, CA (K.W.M., R.A.H.).
² From University of North Carolina, Chapel Hill (M.A.C.); Brigham and Women's Hospital, Heart and Vascular Center, Harvard Medical School, Boston, MA (D.L.B.); Columbia University, New York, NY (G.W.S.); University of Auckland, Auckland City Hospital, Auckland, New Zealand (H.D.W.); Université Paris-Diderot, Sorbonne Paris Cité, INSERM U-1148, DHU FIRE, Hópital Bichat, Assistance Publique-Hópitaux de Paris, Paris, France (P.G.S.); Institute of Cardiovascular Medicine and Science, National Lung and Heart Institute, Imperial College, Royal Brompton Hospital, London, United Kingdom (P.G.S.); Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA (C.M.G.); Kerckhoff Clinic and Thoraxcenter, Bad Nauheim, Germany (C.W.H.); Scripps Clinic, La Jolla, CA (M.J.P.); UOC Fondazione IRCCS Policlinico San Matteo, Pavia, Italy (S.L.); The Medicines Company, Parsippany, NJ (J.P., E.N.D.); and Stanford University, Palo Alto, CA (K.W.M., R.A.H.). dlbhattmd@post.harvard.edu.

PMID: 27482008
PMCID: PMC5006794
DOI: 10.1161/CIRCULATIONAHA.115.020829

Abstract

Background: Cangrelor is an intravenous P2Y12 inhibitor approved to reduce periprocedural ischemic events in patients undergoing percutaneous coronary intervention not pretreated with a P2Y12 inhibitor.

Methods: A total of 11 145 patients were randomized to cangrelor or clopidogrel in the CHAMPION PHOENIX trial (Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition). We explored the effects of cangrelor on myocardial infarction (MI) using different definitions and performed sensitivity analyses on the primary end point of the trial.

Results: A total of 462 patients (4.2%) undergoing percutaneous coronary intervention had an MI as defined by the second universal definition. The majority of these MIs (n=433, 93.7%) were type 4a. Treatment with cangrelor reduced the incidence of MI at 48 hours (3.8% versus 4.7%; odds ratio [OR], 0.80; 95% confidence interval [CI], 0.67-0.97; P=0.02). When the Society of Coronary Angiography and Intervention definition of periprocedural MI was applied to potential ischemic events, there were fewer total MIs (n=134); however, the effects of cangrelor on MI remained significant (OR, 0.65; 95% CI, 0.46-0.92; P=0.01). Similar effects were seen in the evaluation of the effects of cangrelor on MIs with peak creatinine kinase-MB ≥10 times the upper limit of normal (OR, 0.64; 95% CI, 0.45-0.91) and those with peak creatinine kinase-MB ≥10 times the upper limit of normal, ischemic symptoms, or ECG changes (OR, 0.63; 95% CI, 0.48-0.84). MIs defined by any of these definitions were associated with increased risk of death at 30 days. Treatment with cangrelor reduced the composite end point of death, MI (Society of Coronary Angiography and Intervention definition), ischemia-driven revascularization, or Academic Research Consortium definite stent thrombosis (1.4% versus 2.1%; OR, 0.69; 95% CI, 0.51-0.92).

Conclusions: MI in patients undergoing percutaneous coronary intervention, regardless of definition, remains associated with increased risk of death in the current era. Cangrelor compared with clopidogrel significantly reduces MI regardless of the definition.

Clinical trial registration: URL: http://clinicaltrials.gov. Unique identifier: NCT01156571.

Keywords: creatine kinase, MB form; myocardial infarction; percutaneous coronary intervention.

PubMed Disclaimer

Figures

**Figure 1.**
**Protocol-defined and sensitivity analyses of primary efficacy end points at 48 hours using different definitions of myocardial infarction (MI).**ARC indicates Academic Research Consortium; CI, confidence interval; CK-MB, creatinine kinase-MB; IDR, ischemia-driven revascularization; OR, odds ratio; SCAI, Society of Coronary Angiography and Intervention; ST, stent thrombosis; and ULN, upper limit of normal.

**Figure 2.**
**Sensitivity analyses evaluating outcomes at 48 hours of cangrelor compared with clopidogrel using different definitions of myocardial infarction (MI).**Time to first occurrence of (A) death, MI (Society of Coronary Angiography and Intervention [SCAI] definition), ischemia-driven revascularization (IDR), and Academic Research Consortium (ARC) definite stent thrombosis (ST) and (B) death, MI (creatinine kinase-MG [CK-MB] ≥10 times the upper limit of normal [ULN]), IDR, and ARC definite stent thrombosis. OR indicates odds ratio.

**Figure 3.**
**Association between the types of myocardial infarction (MI) using various definitions and the risk of death at 30 days.**CHF indicates coronary heart failure; CI, confidence interval; CK-MB, creatinine kinase-MB; MI, myocardial infarction; OR, odds ratio; PCI, percutaneous coronary intervention; SCAI, Society of Coronary Angiography and Intervention; and ULN, upper limit of normal.

See this image and copyright information in PMC

References

1. Bhatt DL, Stone GW, Mahaffey KW, Gibson CM, Steg PG, Hamm CW, Price MJ, Leonardi S, Gallup D, Bramucci E, Radke PW, Widimský P, Tousek F, Tauth J, Spriggs D, McLaurin BT, Angiolillo DJ, Généreux P, Liu T, Prats J, Todd M, Skerjanec S, White HD, Harrington RA. Platelet inhibition with cangrelor during PCI. N Engl J Med. 2013;369:393–395. - PubMed
1. Thygesen K, Alpert JS, White HD Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Eur Heart J. 2007;28:2525–2538. doi: 10.1093/eurheartj/ehm355. - PubMed
1. Généreux P, Stone GW, Harrington RA, Gibson CM, Steg PG, Brener SJ, Angiolillo DJ, Price MJ, Prats J, Lasalle L, Liu T, Todd M, Skerjanec S, Hamm CW, Mahaffey KW, White HD, Bhatt DL CHAMPION PHOENIX Investigators. Impact of intraprocedural stent thrombosis during percutaneous coronary intervention: insights from the CHAMPION PHOENIX Trial (Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention). J Am Coll Cardiol. 2014;63:619–629. doi: 10.1016/j.jacc.2013.10.022. - PubMed
1. Leonardi S, Mahaffey KW, White HD, Gibson CM, Stone GW, Steg GW, Hamm CW, Price MJ, Todd M, Dietrich M, Gallup D, Liu T, Skerjanec S, Harrington RA, Bhatt DL. Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial. Am Heart J. 2012;163:768–776.e2. doi: 10.1016/j.ahj.2012.02.018. - PubMed
1. Moussa ID, Klein LW, Shah B, Mehran R, Mack MJ, Brilakis ES, Reilly JP, Zoghbi G, Holper E, Stone GW. Consideration of a new definition of clinically relevant myocardial infarction after coronary revascularization: an expert consensus document from the Society for Cardiovascular Angiography and Interventions (SCAI). J Am Coll Cardiol. 2013;62:1563–1570. doi: 10.1016/j.jacc.2013.08.720. - PMC - PubMed

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

Associated data

Actions
- Search in PubMed
- Search in ClinicalTrials.gov

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Medical
- ClinicalTrials.gov
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition)

Affiliations

Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition)

Authors

Affiliations

Abstract

Figures

References

Publication types

MeSH terms

Substances

Associated data

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Miscellaneous